OXAPIUM

Details

Stereochemistry	MIXED
Molecular Formula	C22H34NO2
Molecular Weight	344.5109
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 3
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+]4(CC1COC(O1)(C2CCCCC2)C3=CC=CC=C3)CCCCC4

InChI

InChIKey=AXWZZEWIGNYBGA-UHFFFAOYSA-N

InChI=1S/C22H34NO2/c1-23(15-9-4-10-16-23)17-21-18-24-22(25-21,19-11-5-2-6-12-19)20-13-7-3-8-14-20/h2,5-6,11-12,20-21H,3-4,7-10,13-18H2,1H3/q+1

HIDE SMILES / InChI

Molecular Formula	C22H34NO2
Molecular Weight	344.5109
Charge	1
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.epharmapedia.com/medicine/profile/204618/Esperan.html?lang=en&tab=druginfo
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01815 and http://america.pink/oxapium-iodide_3370799.html

Oxapium iodide (ciclonium or cyclonium, trade name Oxaperan, Esperan) is an antispasmodic indicated for the treatment of gastritis, gastroduodenal ulcer, enteritis, and other conditions. It is marketed in South Korea by Dongsung Pharmaceuticals and by Taisho Toyama Pharmaceutical Co., Ltd. in Japan. Oxapium is a muscarinic cholinergic receptor antagonist. It has two separate pharmacological effects: (1) a potent atropine-like action, (2) a papaverine-like action.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?D01815	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Gastritis 46 Sources: http://wenku.baidu.com/view/9f253b3010661ed9ad51f317.html?re=view	Palliative	Approved 8583	ESPERAN Approved Use Improvement of pain due to spasms and motility disorder in the following diseases: Gastritis, Gastroduodenal ulcer, Enteritis, Gallbladder and biliary disease, Urinary calculus Launch Date 1971
Enteritis 5 Sources: http://wenku.baidu.com/view/9f253b3010661ed9ad51f317.html?re=view	Palliative	Approved 8583	ESPERAN Approved Use Improvement of pain due to spasms and motility disorder in the following diseases: Gastritis, Gastroduodenal ulcer, Enteritis, Gallbladder and biliary disease, Urinary calculus Launch Date 1971
Gallbladder disease 13 Sources: http://wenku.baidu.com/view/9f253b3010661ed9ad51f317.html?re=view	Palliative	Approved 8583	ESPERAN Approved Use Improvement of pain due to spasms and motility disorder in the following diseases: Gastritis, Gastroduodenal ulcer, Enteritis, Gallbladder and biliary disease, Urinary calculus Launch Date 1971

PubMed

Title	Date	PubMed
[The effects of 1,3-dioxolane derivative (Esperan) on the smooth muscle and its intrinsic nerves of guinea-pig stomach (author's transl)].	1974-03	4471926

Patents

Sample Use Guides

In Vivo Use Guide

For oral use, the usual adult dosage is 30-60 mg as oxapium iodide daily in 3 divided doses.

Route of Administration: Oral

In Vitro Use Guide

The excitatory nerve response by electrical stimulation was rapidly and completely suppressed by Oxapium (esperan) (0.1 ug/m/)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:04:54 GMT 2025` Edited by `admin` on `Mon Mar 31 21:04:54 GMT 2025`
Record UNII	IK8HSQ3YBL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXAPIUM

Common Name

English

OXAPIUM ION

Preferred Name

English

OXAPIUM CATION

Common Name

English

PIPERIDINIUM, 1-((2-CYCLOHEXYL-2-PHENYL-1,3-DIOXOLAN-4-YL)METHYL)-1-METHYL-

Systematic Name

English

Oxapium [WHO-DD]

Common Name

English

CYCLONIUM

Common Name

English

Code System Code Type Description

PUBCHEM

4613